Insider Trading March 26, 2026

Macy’s Controller Disposes of 379 Shares, Retains More Than 24,000

Paul Griscom sold $7,105 of stock after exercising RSUs; company upbeat on Q4 2025 but delivered cautious 2026 guidance

By Sofia Navarro M
Macy’s Controller Disposes of 379 Shares, Retains More Than 24,000
M

Macy’s senior finance executive Paul Griscom sold 379 shares of common stock on March 25, 2026, for $7,105 after exercising restricted stock units the prior day. The retailer reported a fourth-quarter 2025 beat on revenue and adjusted EPS, while several analysts trimmed price targets and management issued initial fiscal 2026 guidance below Wall Street expectations.

Key Points

  • Griscom sold 379 shares on March 25, 2026, for a total of $7,105 after exercising 1,139 restricted stock units on March 24, 2026.
  • Macy’s beat fourth-quarter 2025 estimates with adjusted EPS of $1.67 and revenue of $7.6 billion; same-store sales rose 1.8%, led by fragrance and luxury.
  • Several analysts trimmed price targets following results while Jefferies maintained a Buy; initial fiscal 2026 guidance came in below Wall Street expectations.

Paul Griscom, senior vice president and Controller at Macy’s, sold 379 shares of the company’s common stock on March 25, 2026. The transactions were executed at prices spanning $18.715 to $18.775 per share, producing an average sale price of $18.7492 and total proceeds of $7,105.

The day prior, on March 24, 2026, Griscom exercised 1,139 restricted stock units that converted into common shares. Those units carried a price of $0. After the March transactions, Griscom directly holds 24,139 shares of Macy’s common stock.

The insider sale occurred while Macy’s shares were trading near a fair value estimate of $18.52. Over the trailing 12 months the stock has risen roughly 46%, although it is down about 15% year-to-date. The company’s market multiples included a price-to-earnings ratio of 7.92, and the shares offered a dividend yield of 4.14% at the time of the report.

Macy’s reported fourth-quarter fiscal 2025 results that topped consensus expectations. The retailer delivered adjusted diluted earnings per share of $1.67 versus an analyst forecast of $1.56, and revenue of $7.6 billion compared with a projected $7.46 billion. Management attributed the quarter’s strength in part to performance in fragrance and luxury categories, and the company recorded total-company same-store sales growth of 1.8% for the period.

Following the results, several brokerages adjusted their price targets and ratings. TD Cowen lowered its price target to $20 from $21 while keeping a Hold rating. Telsey reduced its target to $20 from $25 and maintained a Market Perform rating, citing macro uncertainty. Evercore ISI cut its target to $19 from $21 and kept an In Line rating, pointing to valuation concerns. Jefferies reiterated a Buy rating with a $22 price target and referenced the fourth-quarter outperformance.

Management’s initial guidance for fiscal 2026 came in below Wall Street expectations. Company commentary indicated that the outlook was influenced by accounting changes and planned store closures.


Contextual note: The insider transaction was relatively small in dollar terms but occurred amid a mix of encouraging quarterly results and more cautious forward guidance, along with analyst target revisions.

Risks

  • Initial fiscal 2026 guidance that was below Wall Street estimates, which may weigh on investor expectations for the retail sector.
  • Analyst concerns about valuation and macroeconomic uncertainty, reflected in lowered price targets, could pressure Macy’s equity performance.
  • Planned store closures and accounting changes noted by management may introduce near-term operational and reporting uncertainty for the company.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026